01:54 PM EDT, 04/28/2025 (MT Newswires) -- CG Oncology ( CGON ) on Monday reported best-in-disease durability data in its phase 3 BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec.

Shares jumped 28% as intraday trading volume soared to over 6.58 million from a daily average of about 887,000.

Galmed Pharmaceuticals ( GLMD ) said it has signed a binding term sheet with Entomus for a license deal to develop and commercialize a novel semaglutide sublingual formulation.

Shares rose 17% as trading volume catapulted to more than 57 million from a daily average of about 895,000.

Portage Biotech ( PRTG ) shares rose 20% after the firm reported confirmatory preclinical results in a murine mesothelioma model supporting first-in-human trial of PORT-7.

More than 8.23 million shares traded intraday, compared with a daily average of about 1.25 million.

Price: 28.81, Change: +6.44, Percent Change: +28.79